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CASE REPORT
A puerperal patient with agranulocytosis during 
tazobactam / piperacillin administration : A case report
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Abstract : Tazobactam / piperacillin (TAZ / PIPC) is an injectable combination drug consisting of a broad-spec-
trum penicillin and a β-lactamase inhibitor. This antimicrobial has a wide spectrum of efficacy against both 
Gram-positive bacteria and anaerobes. Adverse events usually present as diarrhea or liver dysfunction ; agranu-
locytosis has not been reported in Japanese patients with puerperal disorders. However, we report a 32-year-old 
Japanese woman who received TAZ / PIPC to treat an intraperitoneal infection that developed after complica-
tions related to transvaginal delivery. Within 14 days of beginning TAZ / PIPC therapy, the patient developed 
agranulocytosis, indicated by a white blood cell count of 1900 cells / µL and a neutrophil count of 475 cells / µL. We 
discontinued TAZ / PIPC at this point and changed the antimicrobial to meropenem. Seven days later, her white 
blood cell count increased to 3700 cells / µL (neutrophil count : 1684 cells / µL), and the intraperitoneal infection 
resolved. Patients receiving TAZ / PIPC should be monitored periodically for agranulocytosis as well as for diar-
rhea and liver dysfunction. J. Med. Invest. 68 : 368-371, August, 2021
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INTRODUCTION
 
Tazobactam / piperacillin (TAZ / PIPC) is a combination an-
tibiotic preparation for injection consisting of a β-lactamase 
inhibitor, tazobactam (TAZ), and a penicillin antibiotic, pipera-
cillin (PIPC), at a ratio of 1 : 8 (1). As TAZ / PIPC has a broad 
antimicrobial spectrum against Gram-positive bacteria, such as 
Staphylococcus, gram-negative bacteria, including Pseudomonas 
aeruginosa, and anaerobic bacteria (2), it is routinely used clini-
cally to treat many infectious diseases (3). In Japan, the drug’s 
indications for pneumonia, pyelonephritis, and peritonitis are 
covered by health insurance. In the Guidelines for the Treatment 
of Respiratory Infectious Diseases, TAZ / PIPC is recommended 
as a first-choice drug for hospital-acquired pneumonia (HAP), 
nursing- and healthcare-associated pneumonia (NHCAP), and 
severe pneumonia (4). In the United States, TAZ / PIPC and 
carbapenem preparations are recommended as drugs for mono-
therapy in the guidelines for the management of intraperitoneal 
infectious diseases collaboratively announced by the Surgical 
Infection Society and Infectious Diseases Society of America in 
2010. As primary adverse reactions, diarrhea and liver dysfunc-
tion have been reported, but no case report of agranulocytosis as 
a serious adverse event has been published in Japanese patients 
with puerperal disorders. We report a patient in whom the ad-
ministration of TAZ / PIPC for intraperitoneal infection during 
puerperium may have induced agranulocytosis. 
CASE PRESENTATION
Patient : A 32-year-old female patient.
Complaint : Delivery.
Medical history : Hypothyroidism.
Therapeutic drug : Levothyroxine sodium hydrate.
Family history : Not contributory.
Obstetric history : gravidity, 0 ; parity, 0.
Allergy : Not contributory.
Present illness : She was admitted due to premature rupture 
of the fetal membranes (Day 5 in Week 39 of pregnancy).
Laboratory data on admission : The laboratory data on admis-
sion are presented in the Table.
Physical examination on admission : The patient’s height, 
body weight, body temperature, heart rate, and blood pressure 
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Table.　Laboratory data on Day 4
WBC 98.40 ×102 / µL TP 6.4 g / dL
Seg 83.2 ％ ALB 3.0 g / dL
Eosin 0.0 ％ AST 16 U / L
Baso 0.2 ％ ALT 8 U / L
Lymph 11.7 ％ LDH 184 U / L
Mono 4.9 ％ BUN 5.6 mg / dL
RBC 40.4 ×105/ µL Cr 0.37 mg / dL
HGB 10.8 g / dL eGFR 157.3 mL / min
PLT 20.3 ×104/ µL CRP 5.68 mg / dL
WBC : white blood cell count, Seg : segmented neutrophils, Eosin : eo-
sinophils, Baso : basophils, Lymph : lymphocytes, Mono : monocytes, 
RBC : red blood cells, HGB: hemoglobin, PLT : platelets, TP : total 
protein, ALB : albumin, AST : aspartate aminotransferase, ALT : al-
anine aminotransferase, LDH : lactate dehydrogenase, BUN : blood 
urea nitrogen, Cr : creatinine, eGFR : estimated glomerular filtration 
rate, CRP : C-reactive protein
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were 155.8 cm, 54.5 kg, 37.2°C, 115 beats / min, and 130 / 87 
mmHg, respectively.
Course after admission : After admission, delivery was in-
duced using oxytocin, and on Day 4, a neonate was born by 
transvaginal delivery. After delivery, placental separation-re-
lated hemorrhage persisted, making management by ligation 
and blood transfusion difficult ; therefore, total hysterectomy 
was performed on the same day. From Day 8, fever ( ≥ 38°C) 
persisted, and blood culture revealed Bacterioides fragilis on Day 
9, suggesting intraperitoneal infection as an etiological factor. 
TAZ / PIPC therapy (4.5 g, every 8 hours) was started. Subse-
quently, the leukocyte count gradually decreased to 1900 / µL 
on Day 23 (neutrophil count : 475 / µL), leading to a diagnosis of 
agranulocytosis. There was no change in the red blood cell count 
(RBC). There was a slight decrease in the platelet count (PLT), 
but the value did not meet the diagnostic criterion for throm-
bopenia. In addition, there were no changes in the eosinophil or 
basophil count in comparison with the values at admission.
Drug-induced agranulocytosis was suspected, and TAZ / PIPC 
administration was promptly discontinued. Considering the 
drug susceptibility of Bacterioides fragilis and breast milk trans-
fer, TAZ / PIPC was changed to meropenem (MEPM) (1 g every 
8 hours). Subsequently, granulocyte-colony stimulating factor 
(G-CSF) was not used, and the leukocyte count returned to 
3920 / µL on Day 27 (neutrophil count : 1784 / µL). Concerning 
the intraperitoneal infection, a reduction in the inflammatory 
response and fever resolution were noted 2 weeks after confirm-
ing a negative blood culture. MEPM therapy ended on Day 30. 
Subsequently, there was no recrudescence of agranulocytosis or 




We report a patient with agranulocytosis related to TAZ / PIPC 
administration during puerperium. Agranulocytosis related to 
drugs, excluding anticancer drugs, is characterized by a neu-
trophil count of ≤ 500 / µL, and this adverse event is rare (5). Its 
incidence is 1–5 person-years per 1,000,000 persons (6). Drugs 
are involved in the etiology of agranulocytosis in approximately 
70% of patients (7).
As drugs that frequently cause agranulocytosis, anti-thyroid 
drugs, antibiotics, and antipsychotics are known, but only a 
few patients with TAZ / PIPC-induced agranulocytosis have 
been reported (8-12) ; no puerperal patient has been reported. 
A definitive diagnosis of drug-induced agranulocytosis can be 
made if there is a decrease in the granulocyte count after drug 
administration in the absence of other factors causing granulo-
cytopenia. However, a decrease in the granulocyte count is not 
rare in severe-status patients, especially those with infection. 
Conditions to be differentiated from acute agranulocytosis are 
viral / bacterial infection, bone marrow failure syndrome, hyper-
splenism, and drug-induced agranulocytosis (13). In the present 
case, we were unable to definitively conclude that TAZ / PIPC in-
duced the granulocytopenia. However, considering the reduction 
in the abscess after the start of TAZ / PIPC therapy and the pa-
tient’s recovery from protracted leukopenia to a leukocyte count 
of 5480 / µL (neutrophil count : 3162 / µL) 12 days after discontin-
uing TAZ / PIPC administration despite few imaging findings 
suggestive of infection, TAZ / PIPC may have been etiologically 
involved in the protracted granulocytopenia in the present case. 
In addition to TAZ / PIPC, levothyroxine sodium was adminis-
tered before admission to treat hypothyroidism ; however, no 
study has reported agranulocytosis related to levothyroxine 
sodium. Moreover, hematology on admission revealed no abnor-
malities in the leukocyte or neutrophil counts. Therefore, the 
possibility of levothyroxine sodium-induced agranulocytosis was 
excluded, and TAZ / PIPC may have induced the agranulocytosis. 
However, bone marrow examination was not conducted and a 
definitive diagnosis was not made, being a limitation.
Although the etiology of drug-induced agranulocytosis re-
mains unclear, two mechanisms, direct toxicity and an immune 
mechanism, have been proposed (14). 
Figure.　Leukocyte, neutrophil, red blood cell and platelet counts, C-reactive protein, and body tempurature 
throughout the patient’s hospitalization period
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In Japan, the reported incidences of TAZ / PIPC- and PIPC-in-
duced agranulocytosis are 0.1 to 5% and unclear, respectively, 
in the package inserts. We searched for “agranulocytosis” using 
a system to search for adverse reactions to drugs based on the 
“Japanese Adverse Drug Event Report database” announced 
on the Pharmaceuticals and Medical Devices Agency (PMDA) 
homepage, Drug Information Finding Outcomes (DRIFOs). For 
the respective drugs, 30 and 14 patients were found, respective-
ly. There was no puerperal disorder in either series. TAZ / PIPC 
used in the present case is a combination drug that may induce 
adverse reactions. However, there is no commercially available 
product consisting of TAZ alone and no study has reported that 
the addition of TAZ to PIPC increases the risk of adverse reac-
tions ; therefore, comparison may be difficult. On the other hand, 
penicillin-induced agranulocytosis has been reported ; therefore, 
in the present case, the adverse reaction may have been related 
to PIPC.
Regarding the cross-reactivity of TAZ / PIPC and MEPM, the 
probability of cross-reactions with carbapenems in patients with 
penicillin allergy was previously considered to be approximately 
50%. However, this was based on a single study involving a small 
number of patients (15). A recent study reported that cross-re-
actions with carbapenems occurred in <1% of patients with 
penicillin allergy (16).
Concerning direct toxicity, antiepileptic and-psychotic drugs 
were reported to directly act on myeloid cells. The toxicity is 
induced by the drug itself, a toxic metabolite, or an accessory 
product. Leukopenia related to direct toxicity develops slowly. In 
comparison, an immune mechanism is termed a “drug allergy” 
in some cases, and drug adsorption / immune complex / auto-
immune mechanisms are known to occur. The onset of a drug 
allergy is more rapid than a toxicity. Antibody is produced 
within 1 hour to 1 day in patients previously sensitized to the 
drug, and in 7–10 days in non-sensitized patients. Concerning 
penicillin antibiotics, an immune mechanism may be involved in 
the onset of agranulocytosis. In the present case, leukocytopenia 
and neutropenia were observed 14 days after the administration 
of TAZ / PIPC. This is consistent with the timing of agranulo-
cytosis onset possibly related to an immune mechanism, which 
is supported by previous studies stating that adverse reactions 
developed 11–17 days after the use of TAZ / PIPC (11, 17). Fur-
thermore, the risk factors for agranulocytosis are advanced age, 
female sex, renal hypofunction, and autoimmune diseases (18, 
19). However, in the present case, the patient was 32 years old, 
and the creatinine clearance (Ccr) (Cockcroft–Gault equation) 
was 165.58 mg / dL ; there was no renal hypofunction. There was 
also no history of autoimmune disease. 
The agranulocytosis-related mortality rate with TAZ / PIPC is 
approximately 10%, and agranulocytosis accounts for 20%–30% 
of drug-related deaths, and is the most frequent causative factor. 
As protracted / severe neutropenia increases the mortality rate, 
initial management is important. Therefore, when administer-
ing TAZ / PIPC to puerperal patients, neutrophil counts should 
be monitored to detect agranulocytosis, in addition to monitor-
ing for diarrhea and evaluating liver function.
In the present case, bacteremia due to hospital-onset intraper-
itoneal infection was noted. To cover the Gram-positive bacteria 
suspected to be the causative bacteria in addition to Bacterioides 
fragilis, which was detected on blood culture, CFPM + CLDM or 
MNZ, a quinolone + CLDM or MNZ, or carbapenem antibiotics 
are considered options. In the present case, it was necessary to 
select a highly safe drug with low breast milk transfer, consid-
ering lactation. CLDM may affect the intestinal flora of children 
fed breast milk. The carcinogenicity of MNZ in animals and its 
mutagenicity in humans were previously demonstrated ; there-
fore, healthy infants may be exposed to metronidazole via breast 
milk (20). Considering the safety, according to these studies, 
MEPM with its low-level breast milk transfer was proposed as 
an alternative to TAZ / PIPC (21), preventing the unnecessary 
discontinuation of lactation.
In conclusion, we reported a patient with agranulocytosis 
related to TAZ / PIPC administered during the puerperal period. 
On the basis on the patient’s previous drug administration histo-
ry, we considered that agranulocytosis was related to TAZ / PIPC 
and discontinued the drug, resulting in recovery. When admin-
istering TAZ / PIPC, neutrophil counts should be monitored to 
detect agranulocytosis, in addition to monitoring for diarrhea 
and evaluating liver function. Furthermore, drug administra-
tion should be discontinued at the onset of agranulocytosis, and 
TAZ / PIPC should be changed to other drugs, if necessary.
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